findmyKOL

Taofeek Owonikoko, MD

Enriched profile

Kevin J. Cullen, M.D. Distinguished Professor of Oncology; Executive Director, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center; Chief of Service, University of Maryland Medical Center; Senior Associate Dean for Cancer Programs and Associate Vice President for Cancer Programs, University of Maryland School of Medicine / UMB · University of Maryland School of Medicine

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Baltimore, MD · Northeast · United StatesSpecialtyHematology / OncologyFocusLung Cancer Treatments and Mutations+4
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2021–2026

Taofeek Owonikoko is Kevin J. Cullen, M.D. Distinguished Professor of Oncology; Executive Director, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center; Chief of Service, University of Maryland Medical Center; Senior Associate Dean for Cancer Programs and Associate Vice President for Cancer Programs, University of Maryland School of Medicine / UMB at University of Maryland School of Medicine. OpenAlex indexes 708 publications with 66,624 citations (h-index 89); ClinicalTrials.gov lists 12 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 15 Oct 2026

Taofeek Kunle Owonikoko, MD, is Kevin J. Cullen, M.D. Distinguished Professor of Oncology at University of Maryland School of Medicine / University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), Baltimore, MD. The public record shows 708 publications with 66,624 citations (h-index 89), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 29 companies, 4 NIH-funded awards (2021–2026).

  • Most recent indexed publication: 2026 · JCO oncology practice
  • Top research focus: Lung Cancer Treatments and Mutations
  • 12 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 29 companies

Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)6 trialsSmall Cell Lung Carcinoma3 trialsCarcinoma, Small Cell2 trialsHead & Neck Cancer1 trialCarcinoma, Squamous Cell1 trialNeuroendocrine Tumors1 trialCysts1 trialCarcinoma, Neuroendocrine1 trialCarcinoma, Papillary1 trialMelanoma1 trialSarcoma1 trialNeuroblastoma1 trialComa1 trial

Research focus

OpenAlex concept fingerprint
Lung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Immunotherapy and BiomarkersCancer Genomics and DiagnosticsCancer therapeutics and mechanisms

Drugs & molecules

across trials, industry payments and publications
Libtayogeneric · CemiplimabClinical trials—Industry payments14Publications1Tagrissogeneric · OsimertinibClinical trials—Industry payments6Publications2Imfinzigeneric · DurvalumabClinical trials—Industry payments6Publications1Tecentriqgeneric · AtezolizumabClinical trials—Industry payments3Publications1Imdelltrageneric · TarlatamabClinical trials—Industry payments1Publications2Cabometyxgeneric · CabozantinibClinical trials—Industry payments1Publications1Lumakrasgeneric · SotorasibClinical trials—Industry payments10Publications—Trodelvygeneric · SacituzumabClinical trials—Industry payments4Publications—Zepzelcageneric · LurbinectedinClinical trials—Industry payments4Publications—Ilarisgeneric · CanakinumabClinical trials—Industry payments3Publications—Rybrevantgeneric · AmivantamabClinical trials—Industry payments2Publications—Calquencegeneric · AcalabrutinibClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
AstraZeneca Pharmaceuticals LPClinical trials—Industry payments20Daiichi Sankyo Inc.Clinical trials—Industry payments17Regeneron Pharmaceuticals, Inc.Clinical trials—Industry payments15Amgen Inc.Clinical trials—Industry payments14AstraZeneca UK LimitedClinical trials—Industry payments13Boehringer Ingelheim International GmbHClinical trials—Industry payments6Emory UniversityClinical trials6Industry payments—Gilead Sciences, Inc.Clinical trials—Industry payments6Genentech USA, Inc.Clinical trials—Industry payments5Janssen Scientific Affairs, LLCClinical trials—Industry payments5Novartis Pharmaceuticals CorporationClinical trials—Industry payments5Jazz Pharmaceuticals Inc.Clinical trials—Industry payments4Puma Biotechnology, Inc.Clinical trials—Industry payments4Eli Lilly and CompanyClinical trials—Industry payments3E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments2F. Hoffmann-La Roche AGClinical trials—Industry payments2National Cancer Institute (NCI)Clinical trials2Industry payments—University of Maryland, BaltimoreClinical trials2Industry payments—Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments1BeiGene, Ltd.Clinical trials—Industry payments1Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments1Eagle Pharmaceuticals, Inc.Clinical trials—Industry payments1Eisai Inc.Clinical trials—Industry payments1Exelixis Inc.Clinical trials—Industry payments1Genentech, Inc.Clinical trials—Industry payments1Genmab U.S., Inc.Clinical trials—Industry payments1Ipsen Biopharmaceuticals, IncClinical trials—Industry payments1Janssen Biotech, Inc.Clinical trials—Industry payments1Janssen Global Services, LLCClinical trials—Industry payments1Merck KGaAClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
708publications

Distinct works indexed by OpenAlex, matched via ORCID; 35 in PubMed.

66,624citations

Total citations across indexed works.

89h-index

Hirsch index (OpenAlex). i10-index 262.

Clinical & industry

trials, payments and federal funding
12clinical trials

Investigator role on registered studies.

View trials ↓
29companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
4NIH grants · 2021–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 15 Oct 2026

Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:

All 12 trial records: search, sort and filter.Explore →

Industry payments

Updated 15 Oct 2026

29 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 53 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    32.1%
    l-Thyroxine32.1%
    Levothyroxine Sodium100%
    Part D<11 patients

  • Nervous system

    25%
    Phenothiazine25%
    Prochlorperazine Maleate100%
    Part D<11 patients

  • Metabolism & gastrointestinal

    21.4%
    Serotonin-3 Receptor Antagonist21.4%
    Ondansetron Hcl100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 15 Oct 2026

4 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:

All 29 award records: search, sort and filter.Explore →

Congress activity

Updated 15 Oct 2026

188 congress contributions (2009–2025) across AACR, ASCO, ASTRO, ENDO, ESMO per OpenAlex. The most recent:

All 188 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 15 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 35 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    The Immune Landscape of Cancer
    Article6,255 citations2018
    doi.org ↗
  2. 02
    An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
    Article3,980 citations2018
    doi.org ↗
  3. 03
    Oncogenic Signaling Pathways in The Cancer Genome Atlas
    Article3,392 citations2018
    doi.org ↗
  4. 04
    Genomic Classification of Cutaneous Melanoma
    Article3,267 citations2015
    doi.org ↗
  5. 05
    Integrated Genomic Characterization of Papillary Thyroid Carcinoma
    Article3,096 citations2014
    doi.org ↗
All 708 cited works: search, sort and filter.Explore →

Network

Updated 15 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Suresh S. Ramalingam383Fadlo R. Khuri273Shi‐Yong Sun156Gabriel Sica155Madhusmita Behera119Walter J. Curran118Zhengjia Chen95Xingming Deng95Nabil F. Saba91Dong M. Shin89Conor Steuer82Rathi N. Pillai82Seth Force57Guojing Zhang56Kristin Higgins55Kelly R. Magliocca51Ramaswamy Govindan51R. Donald Harvey48Funda Meric‐Bernstam45Junya Fujimoto40Dongkyoo Park39Gordon B. Mills38Jiajia Gu38Gad Getz37Jean C. Zenklusen37Juok Cho37Nina Thiessen37Yiling Lu37Heidi J. Sofia37Tara M. Lichtenberg37Noreen Dhalla37John N. Weinstein37Miruna Balasundaram37Denise Brooks37Roy Tarnuzzer37Reanne Bowlby37John A. Demchok37Daniel J. Weisenberger37Carolyn M. Hutter37Jay Bowen37

Background & recognition

Updated 15 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Board Certified

    Medical Oncology

    2018
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umaryland.edu ↗
  • PhD in Anatomic Pathology

    Heinrich Heine University, Düsseldorf, Germany

    2001
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umaryland.edu ↗
  • MBChB (medical degree)

    Obafemi Awolowo University, Nigeria

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umaryland.edu ↗
  • MS in Clinical Research

    James T. Laney School of Graduate Studies, Emory University

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umaryland.edu ↗
  • Board Certified

    Hematology and Internal Medicine

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pittwire.pitt.edu ↗

Editorial & leadership roles

journal and society appointments
  • Executive Director

    University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →umms.org ↗
  • Kevin J. Cullen

    M.D. Distinguished Professor of Oncology / Marlene and Stewart Greenebaum Professor in Oncology, Department of Medicine, University of Maryland School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umaryland.edu ↗
  • Chief of Service

    University of Maryland Medical Center (UMMC)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →research.umgccc.org ↗
  • Senior Associate Dean for Cancer Programs

    UMSOM; Associate Vice President for Cancer Programs, University of Maryland, Baltimore

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umaryland.edu ↗
  • Executive Director

    UMSOM Program in Oncology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →umms.org ↗
  • Elected Board Member and Treasurer-elect

    American Society of Clinical Oncology (ASCO)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medschool.umaryland.edu ↗
  • Chartered member

    NCI Clinical Oncology Study Section; ad hoc reviewer, NIH and DOD study sections (11+ years)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medschool.umaryland.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances
  • Podcast guest

    'The Directors: Louis Weiner and Taofeek Owonikoko on keeping up morale amid uncertainty,' The Cancer Letter Podcast

    2025
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancerletter.com ↗
  • Featured profile

    'What's on Greenebaum Cancer Center Executive Director Taofeek K. Owonikoko's Desk?', The Elm / Catalyst Magazine

    2025
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →elm.umaryland.edu ↗
  • Video interview on FDA approval of tarlatamab in extensive-stage small cell lung cancer

    YouTube/OncLive

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
  • Video interview

    Midday Maryland (UMGCCC Facebook)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.